The impact of ten-eleven-translocation 2 (TET2) mutations on response to azacitidine (AZA) in MDS has not been reported. We sequenced the TET2 gene in 86 MDS and acute myeloid leukemia (AML) with 20-30% blasts treated by AZA, that is disease categories wherein this drug is approved by Food and Drug Administration (FDA). Thirteen patients (15%) carried TET2 mutations. Patients with mutated and wild-type (WT) TET2 had mostly comparable pretreatment characteristics, except for lower hemoglobin, better cytogenetic risk and longer MDS duration before AZA in TET2 mutated patients (P ¼ 0.03, P ¼ 0.047 and P ¼ 0.048, respectively). The response rate (including hematological improvement) was 82% in MUT versus 45% in WT patients (P ¼ 0.007). Mutated TET2 (P ¼ 0.04) and favorable cytogenetic risk (intermediate risk: P ¼ 0.04, poor risk: P ¼ 0.048 compared with good risk) independently predicted a higher response rate. Response duration and overall survival were, however, comparable in the MUT and WT groups. In higher risk MDS and AML with low blast count, TET2 status may be a genetic predictor of response to AZA, independently of karyotype.
Introduction
The ten-eleven-translocation 2 (TET2) gene encodes a dioxygenase that converts 5-methylcytosine to 5-hydroxymethylcytosine leading to DNA demethylation at selective loci. It has also been implicated in the regulation of normal myelopoiesis. [1] [2] [3] The TET2 gene is mutated in 15-22% myelodysplastic syndromes (MDS) and acute myeloid leukemia. [4] [5] [6] [7] [8] [9] Prognostic value of TET2 mutations in MDS cohorts treated heterogeneously or in AML treated with intensive chemotherapy remains unclear. 5, 7, 8 Azacitidine (AZA) is a hypomethylating agent yielding 40-60% responses in MDS and AML with low (20-30%) marrow blast count, 10, 11 which is approved in the treatment of those disorders in USA, Europe and other countries. Cytogenetic findings can predict overall survival (OS) with hypomethylating agents, 12, 13 but are relatively poor predictors of response. [13] [14] [15] In a previous cohort of MDS and AML patients (with up to 30% marrow blasts) treated with AZA in a compassionate program, we identified karyotype, BM blasts, and previous low-dose cytarabine (LD AraC) exposure as independent predictors of response, but of those three factors, only cytogenetics independently influenced OS. 13 No consensus genetic predictor of response to hypomethylating agents, in particular to AZA, has been reported so far.
Recently, TET2 loss-of-function has been shown to be associated with a decrease rather than an increase of 5-methylcytosine at the genomic DNA level, 3 which may influence the response to hypomethylating agents. We therefore studied the prognostic value of TET2 mutations in consecutive MDS and low blast count AML treated with AZA.
Patients and methods

Patients
Patients with a World Health Organization (WHO) diagnosis of MDS and X5% marrow blasts or AML with 20-30% marrow blasts (RAEB-t according to FAB classification of MDS 16 ) who initiated AZA treatment in six centers of the Groupe Francophone des Myélodysplasies (GFM) were included in this study, after informed consent. DNA from bone marrow mononucleated cells was collected before AZA treatment, after informed consent.
Treatment
Patients were to receive AZA at the Food and Drug Administration (FDA)/European Medicines Agency (EMEA) approved schedule (75 mg/m 2 per day, 7 days every 4 weeks). Patients having received X1 cycle of AZA and with bone marrow evaluation after X4 cycles, or who died or progressed before completion of four cycles were considered evaluable (those two groups were considered treatment failures).
Responses
Responses were centrally reviewed and scored according to IWG 2006 criteria for MDS. 17 As reaching stable disease (SD) with hematological improvement (HI, defined according to 17 ) with AZA treatment appears to be associated with a survival benefit, 10 this type of response was also considered as a response. The definition of overall response used for univariate and multivariate analyses included complete remission (CR), partial remission (PR), marrow CR (mCR) and SD with HI. Unless otherwise specified, exclusion of HI from responses did not affect the results of analyses.
TET2 gene sequencing
Standard PCR and sequencing of the entire coding sequence (exons 3-11) of the TET2 gene were performed in bone marrow genomic DNA, as previously described. 4 
Statistical analysis
Continuous and dichotomic variables were compared with the Mann-Whitney rank sum test and Fisher's exact tests, respectively. Multivariate analyses were performed by logistic regression. OS was defined from the date of AZA onset until death or censored at last contact. Response duration and OS were estimated with the Kaplan-Meier method and compared with the log-rank test. All tests were two-sided and considered significant when Po0.05. All analyses were performed with the Statview 5.0 (SAS, Cary, NC, USA) and R 2.10.1 (R, Stanford, CA, USA) softwares. 
Results
Patient characteristics
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Fifteen TET2 mutations were found in 13 (15%) patients, including nine frameshift mutations (all inducing a premature STOP codon), three nonsense and three missense mutations, all three in the first conserved domain. 4, 6 Those mutations are recapitulated in Table 2 .
Age, WHO diagnosis, International Prognosis Scoring System risk, white blood cell, neutrophil and platelet counts were comparable in the two groups (all P40.1). However, karyotype according to International Prognosis Scoring System 18 was more favorable in TET2 mutated compared to wild-type (WT) cases: cytogenetic risk was good in 8 (61%), intermediate in 4 (31%) and poor in 1 (8%) patients with mutated TET2, compared with 29 (40%), 11 (15%) and 29 (40%), respectively, in WT cases (P ¼ 0.03). Patients with mutated TET2 also had lower hemoglobin levels (median 8.5 versus 9.4 g/dl, P ¼ 0.047), longer interval from diagnosis (median 13 versus 6 months, P ¼ 0.0046), and tended to have more frequently received previous treatment (46 versus 21%, P ¼ 0.08) than WT TET2 patients.
The proportion of patients who received the full-approved schedule (75 mg/m 2 for 7 days per cycle) was 69 and 75% in the mutated TET2 and WT TET2 groups, respectively (P ¼ 0.7). All cases of early treatment discontinuation (before completion of four cycles) were due to early death or treatment failure. No mutated patient, but seven (10%) WT patients received less than four AZA cycles, because of early death in three cases, and early progression in four cases. Response was evaluated after a median of four cycles in both groups (P ¼ 0.9).
Response to AZA
Response to AZA according to the TET2 status is summarized in Table 3 . The CR rate was 5/13 (38%) in patients with mutated TET2 compared with 15/73 (21%) in TET2 WT patients (P ¼ 0.17). Overall response rate (ORR), including CR, PR and mCR, 17 was 9/13 (69%; CR n ¼ 5, mCR n ¼ 4) in TET2 mutated patients, and 23/73 (31%; CR n ¼ 15,
An additional 13 patients with SD (two mutated and 11 WT patients) achieved HI according to MDS criteria. 17 Including those HI among responses increased the ORR (that is CR, PR, mCR and SD with HI) to 11/13 (85%) in TET2 mutated compared with 34/73 (47%) in TET2 WT patients (P ¼ 0.01).
Multivariate analysis of response to AZA
In univariate analysis, in addition to presence of a TET2 mutation, cytogenetic risk (good: 70%, intermediate: 40%, poor: 37%, P ¼ 0.01) and previous therapy (71% with previous therapy versus 46% in patients receiving AZA frontline, P ¼ 0.049), predicted a higher response rate to AZA. Response rates according to WHO categories were 13/20 (65%) in RAEB-1 (CR n ¼ 8, mCR n ¼ 2, SD with HI ¼ 3), 20/43 (47%) in RAEB-2 (CR n ¼ 6, mCR n ¼ 8, SD with HI n ¼ 6) and 12/23 (52%) in low blast count AML (CR n ¼ 6, PR n ¼ 1, mCR n ¼ 1, SD with HI n ¼ 4). In a multivariate analysis (logistic regression) that included cytogenetic risk, previous therapy and TET2 status, mutated TET2 (P ¼ 0.04) and adverse cytogenetics (intermediate: P ¼ 0.048, poor: P ¼ 0.040), but not previous therapy (P ¼ 0.47) independently predicted a higher ORR (Table 4) . Presence of a TET2 mutation also remained an independent favorable predictive factor when SD with HI was excluded from responses (P ¼ 0.014). Neither baseline hemoglobin levels (P ¼ 0.8) nor previous MDS duration (P ¼ 0.6) affected response rate, and in bivariate analyses, the favorable impact of TET2 mutations on response was independent of baseline hemoglobin and of previous disease duration (both P ¼ 0.02).
Impact of duration of AZA exposure on response TET2 mutated patients received a median of 13 cycles (range: 4-26), compared with 7 (1-39) in WT patients (P ¼ 0.004). Thus, we analyzed whether longer exposure to AZA could have confounded the impact of TET2 status on response achievement. First, patients achieving any type of response (including SD with HI) had received a similar number of AZA cycles in both groups: median 13 cycles (range 4-20) in TET2 MUT patients and 9 cycles (3-36; P ¼ 0.23) in TET2 WT patients. In addition, in a bivariate logistic regression, presence of a TET2 mutation tended to predict an improved ORR (OR ¼ 4.95 (0.99-25.0), P ¼ 0.051) independently of the number of AZA cycles (OR ¼ 1.07 (1.01-1.14), P ¼ 0.049). When SD with HI was excluded from responses, the independent favorable impact of TET2 mutations reached statistical significance (TET2 MUT: OR ¼ 4.29 (1.17-15.63), P ¼ 0.028; number of AZA cycles: OR ¼ 1.04 (0.98-1.10), P ¼ 0.23). As all cases of early AZA discontinuation occurred in WT patients, the influence of TET2 status on ORR was analyzed in the 79 patients having received four or more cycles. In those 79 patients, the ORR (including HI) was 11/13 (85%) in TET2 mutated patients and 33/66 (50%) in TET2 WT patients (P ¼ 0.031). Finally, only 4 of the 45 IWG responses observed in the study occurred after more than six AZA cycles, all of them in the TET2 WT patients. Thus, it is unlikely that the higher response rate of TET2 mutated patients reflects late responses caused by prolonged AZA exposure.
Impact of TET2 mutation type on AZA response
Responses rates were 7/9 (78%, CR: n ¼ 5, mCR/CRi: n ¼ 2) in patients with frameshift mutations, 4/5 (80%, CR: n ¼ 1, mCR/CRi: n ¼ 2, SD with HI: n ¼ 1) with nonsense mutations and 3/3 (100%, CR: n ¼ 1, SD with HI: n ¼ 2) with missense mutations (Table 2) . We analyzed the impact of TET2 status on AZA response excluding those last three missense mutations, considering them as potential previously undescribed polymorphisms, and analyzing them with WT patients. When doing this, the ORR (including HI) was 8/10 (80%) in TET2 mutated patients compared with 37/76 (49%) in TET2 WT patients (P ¼ 0.092) and 8/10 (80%) compared with 24/76 (32%) after excluding SD with HI from responses, respectively (P ¼ 0.005).
Response duration and OS
With a median follow-up of 23.3 months, median response duration was 9.5 months (range: 3.6-17.8 months) in the TET2 mutated versus 12.1 months (range: 1.2-29.0 months) in the TET2 WT group, (P ¼ 0.5; Table 3 ). Median OS from AZA onset was 17.5 months in TET2 mutated and 15.3 months in TET2 WT patients (P ¼ 0.6; Figure 1 ). Median OS of patients who achieved CR was not reached but, in those patients, the 1-year estimate of OS (1-y OS) was 100 and 83% in TET2 mutated and WT cases. In the whole patient population, 1y-OS was 80% in TET2 mutated patients, compared with 86% in the TET2 WT patients (P ¼ 0.32). Seven (8%) patients (all TET2 WT) received allogeneic stem cell transplantation after AZA. Censoring at the time of transplantation did not affect the OS comparison between the two groups (P ¼ 0.6).
Discussion
In our study, presence of a TET2 mutation predicted a higher response rate to AZA, although this did not translate into a benefit in response duration or survival.
The present study included patients with WHO diagnostic categories where AZA is an FDA approved treatment, that is International Prognosis Scoring System high and intermediate 2 (higher risk) MDS, AML with 20-30% (AML 20-30%) marrow blasts (former RAEB-T), and also some lower risk MDS with symptomatic cytopenias. We only included, in the last category, patients with an excess of marrow blasts, as marrow response TET2 mutations in azacitidine treated MDS and AML R Itzykson et al cannot be assessed in patients without excess blasts. 10 In addition, 85% of the patients had higher risk MDS or AML 20-30%, that is categories were AZA significantly improved survival over conventional treatment in the pivotal AZA 001 trial. 10 In the 86 patients analyzed, we found a 15% rate of TET2 mutations, in line with previous observations from our group in a different cohort and from other groups, in MDS and AML. [4] [5] [6] [7] [8] [9] The TET2 MUT and WT groups had similar baseline characteristics, except that TET2 mutated patients had more favorable cytogenetics. This was similar to the trend for a lower incidence of TET2 mutations in MDS with a poor cytogenetic risk observed in the largest MDS cohort studied for this mutation to date. 8 ORRs to AZA in MDS and AML (usually taking into account CR, PR, marrow CR and SD with HI) range between 40 and 60%, with only 14-20% CR rates. 10, 11, 13, 19, 20 In our cohort, we found TET2 mutated patients to have a higher ORR than patients with WT TET2 (85 versus 47%, P ¼ 0.01), and a trend for higher CR rates (38 versus 21%, P ¼ 0.17). After excluding SD with HI from overall response definition, TET2 mutations still predicted a higher response rate to AZA (69 versus 31%, P ¼ 0.01).
Using multivariate analysis, the favorable impact of TET2 mutations on response to AZA was found to be independent of baseline characteristics that statistically differed between TET2 mutated and WT cases, that is baseline Hb level, previous disease duration and previous treatment. In addition, the favorable impact of TET2 mutations on response was found to be independent of cytogenetic risk.
A possible bias in our study was the longer exposure to AZA in TET2 mutated patients compared with WT patients. Sufficient duration of AZA treatment indeed appears important to obtain a survival benefit in MDS and AZA maintenance may improve the initial response. 19, 21 In our cohort, however, several lines of evidence support the contention that longer exposure to AZA in the TET2 MUT group was a consequence rather than a cause of higher response rate to AZA, and that the impact of TET2 status was independent of AZA exposure. Indeed, AZA responders received a similar number of cycles in both groups. In addition, the predictive value of TET2 status persisted in bivariate analysis adjusted on the number of cycles, both when including or not SD with HI among responses. Furthermore, there were more early discontinuations of AZA in the WT group, but they were all related to early death or to documented disease progression. When focusing only on patients having received at least four cycles of AZA, the response rate of TET2 MUT patients was still higher. Finally, all late responses occurred in TET2 WT patients, and thus cannot account for the higher response rate of TET2 mutated patients.
Despite the higher response rate of TET2 mutated patients to AZA, we found OS not to be affected by TET2 status. The prognostic value of TET2 on OS in untreated higher-risk MDS or low blast count AML is disputed. Our group reported in a previous patient series better survival in MDS with TET2 mutation, but that cohort had better prognostic characteristics than the present one, as only 7% of the patients had 420% BM blasts, and 13% had a poor cytogenetic risk. 5 In another cohort, also including a minority of higher-risk MDS, TET2 mutations had no prognostic value on OS. 8 However, in both series, only a small minority of patients had received AZA or other treatments aimed at modifying the disease course. In the present study, response duration was also similar in both groups. Therefore, absence of significant OS benefit in TET2 mutated patients despite higher response rates was probably not due to their having shorter response duration than TET2 WT patients, but possibly due to the relatively small numbers and/ or to insufficient follow-up, particularly in CR patients. Prospective studies including larger cohorts of patients receiving AZA or decitabine are warranted to confirm these findings, and establish in particular if potential higher response rate of TET2 mutated patients translate into improved survival.
Prognostic factors of response to hypomethylating agents in MDS and AML remain uncertain. Regarding clinical and biological factors, one study found a lower CR rate in patients with previous therapy or longer MDS duration, 12 whereas other studies did not identify prognostic factors of response achievement. 14, 15 Although encouraging response rates have been found in patients with poor risk cytogenetics in another study, our group previously identified (in another patient cohort) normal karyotype, low BM blast count and absence of previous low-dose AraC exposure as favorable predictors of AZA response. [22] [23] [24] Here, among those three factors, only cytogenetic risk was confirmed as an independent predictor of response (Table 4) .
Biological prognostic factors of response to hypomethylating are also largely unknown. Genetic predictors of response have not been described so far, whereas possible correlations between gene methylation profiles (and/or their evolution with treatment) and results of treatment with hypomethylating agents are controversial. 22, [25] [26] [27] Our results are the first to our knowledge in identifying a genetic predictor of response to a hypomethylating agent, although they will require confirmation in other studies. Patients with TET2 loss-of-function mutations have differentially methylated sites compared with controls, but the majority of these sites are hypomethylated. 3 A lower level of genomic DNA methylation in TET2 mutated patients could increase the sensitivity to AZA and, thus, may explain a better response to this treatment. Recurrent mutations in other genes with epigenetic functions have recently been identified in MDS, including EZH2, 28 UTX and DNMT3A, 29 and the prognostic value of these mutations on response to hypomethylating agents is also being analyzed.
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